Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial - UTU Research Portal

A1 Refereed original research article in a scientific journal

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

Authors: Mesia R, Henke M, Fortin A, Minn H, Ancona ACY, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan ATC, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J

Publisher: ELSEVIER SCIENCE INC

Publication year: 2015

Journal: Lancet Oncology

Journal name in source: LANCET ONCOLOGY

Journal acronym: LANCET ONCOL

Volume: 16

Issue: 2

First page : 208

Last page: 220

Number of pages: 13

ISSN: 1470-2045

DOI: https://doi.org/10.1016/S1470-2045(14)71198-2

Abstract

Interpretation In patients with locally advanced squamous-cell carcinoma of the head and neck, the addition of panitumumab to standard fractionation radiotherapy and cisplatin did not confer any benefit, and the role of EGFR inhibition in these patients needs to be reassessed.